DENVER–Biotechnology firm NanoSphere Health Sciences, LLC, has announced that they have received a patent for their proprietary NanoSphere Delivery System™, a non-invasive delivery technology for “cannabinoids, pharmaceuticals, nutraceuticals, cosmeceuticals, and other biological agent” applications.
A full spectrum of cannabinoids and terpenes is blended in their Evolve NanoSerum™ transdermal formulation, which utilizes the new technology. NanoSerum™ is produced for the medical cannabis market under subsidiary, Evolve Formulas.
“The application is superior because it creates a consistent, reliable dose that is more effective,” described NanoSphere Health Sciences Chief Operations Officer David Sutton. “In most application methods–for example smoking and edibles–cannabis has no reliable dosage as medicine. These other administration methods cause cannabinoids to break down in the users’ digestive system, GI tract, or in the lungs without being fully utilized by the body, resulting in very low bioavailability.
“Utilizing our technology allows us to create fast acting and reliable products with consistent dosing and high bioavailability,” he added.
Nanotechnology is defined as the application of extremely small particles, measured in nano units, and is utilized in several scientific fields including chemistry, biology, physics, materials science, and engineering. A nanometer is one billionth of a meter. The thickness of a piece of newspaper is equal to 100,000 nanometers.
Sutton said the NanoSphere™ delivery system took years of research and development for the company and its team.
“NanoSphere spent five years developing the technology that Dr. Kaufman had been working on for over ten years,” he explained. “The applications it benefits are almost endless. From increasing the effectiveness of dietary supplements and medications, to making better sun screens and cosmeceuticals–for example anti-wrinkle cream. This delivery platform will extend beyond cannabis to vastly improve delivery of ingredients across a wide range of industries.”
At Evolve, Sutton said products will soon be rolling out aimed at providing fast relief for patients using cannabinoids therapeutically, and other medications for various conditions.
“Our upcoming cannabis product pipeline will include fast-acting intranasal and intraoral products that provide effects in minutes. We are also working with nano-encapsulated NSAIDs like Advil and aspirin. There are many more compounds we wish to explore with our technology.”
